Alector reports Q3 net loss $42.2M ($0.43/share); cash $457.2M funds through 2026

Alector, Inc.

2024-Q3 EPS reported -$1.22 revenue$46,318,000

Cash, cash equivalents, investments $457.2M as of Sep 30, 2024, sufficient to fund operations through 2026.
Q3 2024 net loss $42.2M ($0.43 per share) vs $44.5M ($0.53) in Q3 2023; collaboration revenue $15.3M, up from $9.1M.
R&D expenses $48.0M driven by AL101 Phase 2 start; G&A $15.8M includes impairment from lab transition.
FY 2024 guidance: collaboration rev $60-70M, R&D $210-220M, G&A $60-70M.
INVOKE-2 (AL002) Phase 2 data due in 2024; INFRONT-3 (latozinemab) top-line late 2025/early 2026; PROGRESS-AD >1/3 enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.